NCT00402467View on ClinicalTrials.gov

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

PHASE2CompletedINTERVENTIONAL
Enrollment

613

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions
Venous Thromboembolism
Interventions
DRUG

Rivaroxaban (BAY59-7939)

2.5mg bid

DRUG

Rivaroxaban, (BAY59-7939)

5mg bid

DRUG

Rivaroxaban, (BAY59-7939)

10 mg bid

DRUG

Rivaroxaban, (BAY59-7939)

20mg bid

DRUG

Enoxaparine

30mg bid

DRUG

Enoxaparine

30mg bid

Trial Locations (36)

30033

Decatur

32216

Jacksonville

33410

Palm Beach Gardens

33703

St. Petersburg

34239

Sarasota

35205

Birmingham

45219

Cincinnati

75231

Dallas

79410

Lubbock

80012

Aurora

85023

Phoenix

85712

Tucson

91942-3019

La Mesa

90502-2004

Torrance

80011-6798

Aurora

T6G 2B7

Edmonton

T4N 4E7

Red Deer

V1Y 1T2

Kelowna

V6Z 1Y6

Vancouver

R3A 1M3

Winnipeg

E3B 5N5

Fredericton

L4M 6M2

Barrie

P3E 6C3

Greater Sudbury

N2G 1G3

Kitchener

L2G 5X8

Niagara Falls

L1G 2B9

Oshawa

K1H 8L6

Ottawa

K9J 7H8

Peterborough

L4C 4Z3

Richmond Hill

L2R 5K3

St. Catharines

P7B 6V4

Thunder Bay

M3M 2G2

Toronto

L3B 4W6

Welland

C1A 1L2

Charlottetown

H3G 1A4

Montreal

G1J 1Z4

Québec

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY